Volume 32, No 6, Jun 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 6, June 2022: 596-599

LETTERS TO THE EDITOR

Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells

Yarui Ma^1,2,† , Qing Zhu^1,3,† , Xiaobing Wang^1,4,† , Mei Liu¹ , Qichen Chen⁵ , Liming Jiang⁶ , Yihebali Chi⁷ , Yi-Xin Zeng^8,* , Hong Zhao^4,5,* , Yuchen Jiao^1,4,9,*

¹State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China
²Department of Medical Oncology, Beijing Hospital, National Center of Gerontology and Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
³Department of Clinical Laboratory Diagnostics, Beijing Friendship Hospital, Capital Medical University, Beijing, China
⁴Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Beijing, China
⁵National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China
⁶Department of Diagnostic Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China
⁷Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Beijing, China
⁸State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
⁹Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China
^†These authors contributed equally: Yarui Ma, Qing Zhu, Xiaobing Wang
Correspondence: Yi-Xin Zeng(zengyx@sysucc.org.cn)Hong Zhao(zhaohong@cicams.ac.cn)Yuchen Jiao(Jiaoyuchen@cicams.ac.cn)

Dear Editor,

Multiple endocrine neoplasia 1 (MEN1) syndrome, a tumor predisposition disease caused by MEN1 germline mutation, is characterized by combined occurrence of neuroendocrine tumors (NETs) in multiple organs.1 Pancreatic neuroendocrine tumors (PanNETs) are the major cause of the increased mortality in MEN1 patients due to the most malignant potential.1,2 Treatment of NETs with MEN1 is challenging due to concomitant development of multiple tumors and the limited treatment efficiency, where first-line therapy of somatostatin analogues (SSA) shows no more than 10% objective response rate.2 Improved treatments for MEN1 NETs are urgently required.2

https://doi.org/10.1038/s41422-022-00613-1

FULL TEXT | PDF

Browse 444